Document is current
Any future updates will be listed below
-
Authors
Rubio, Jose M.
Kane, John M. https://orcid.org/0000-0002-2628-9442
- License Information
-
More Information
Article History
Received: 2 September 2017
Revised: 14 September 2017
Accepted: 18 September 2017
First Online: 11 October 2017
Competing interests
: Dr. J.M.K. has been a consultant for or received honoraria from Alkermes, Eli Lilly, EnVivo Pharmaceuticals (Forum), Forest (Allergan), Genentech, H. Lundbeck. Intracellular Therapies, Janssen Pharmaceutica, Johnson and Johnson, Neurocrine, Otsuka, Pierre Fabre, Reviva, Roche, Sunovion, Takeda and Teva. Dr. Kane has received grant support from Otsuka and Janssen. Dr. Kane has participated in Advisory Boards for Alkermes, Intracellular Therapies, Lundbeck, Neurocrine, Otsuka, Pierre Fabre, Takeda, Teva. Dr. Kane is a Shareholder in Vanguard Research Group and LB Pharmaceuticals, Inc. Dr J.M.R has nothing to disclose.
